Pyridoxamine ameliorates the effects of advanced glycation end products on subtotal nephrectomy induced chronic renal failure rats

Abstract

Advanced glycation end products (AGEs) contribute to the pathogenesis of renal diseases and have become a new therapeutic target for treatment. Chronic renal failure (CRF) is the end-stage of chronic renal diseases and highly associated with increased incidence in cardiovascular complications, however, some of the pathogenesis has not yet been fully clarified. This study was designed to evaluate the therapeutic or preventive potential of pyridoxamine (PM) against CRF in a 5/6 subtotal nephrectomy rat model. Significant and beneficial contributions to body weight, cardiovascular parameters, clearances of creatinine and BUN and AGEs reduction were observed in CRF rats receiving PM for 8 weeks. PM supplementation might be considered as one of pharmacological strategies for preventing AGE-related pathologies and early stages of renal damage. Prospective trials are needed to elucidate a potential role for PM in adjunctive therapy and to confirm the adequate amount on cardiovascular and renal outcomes in CRF.

Keywords

• Advanced glycation end products
• Pyridoxamine
• Chronic renal failure
• Subtotal nephrectomy